EIF4E and non-small cell lung carcinoma: Because sorafenib did not detectably affect MAPKs in NSCLC cells and its effects on eIF4E phosphorylation were readily seen after 30 min of treatment (Fig. 3A), we hypothesized that this multikinase inhibitor might act directly on MKNKs.